利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

5 条记录 (耗时 0.021 秒)

    Framework residue substituted humanized COL-1 antibodies and their use
    1.
    发明授权
    Framework residue substituted humanized COL-1 antibodies and their use 有权
    框架残基取代人源化COL-1抗体及其用途

    公开(公告)号：US08828717B2

    公开(公告)日：2014-09-09

    申请号：US12946381

    申请日：2010-11-15

    申请人： Jeffrey Schlom ,  Eduardo A. Padlan ,  Rafia Mehdi Kashmiri

    发明人： Syed Kashmiri ,  Jeffrey Schlom ,  Eduardo A. Padlan

    IPC分类号： C12N15/13 ,  C07K16/30 ,  A61K39/00

    CPC分类号： C07K16/3007 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/565

    摘要： The present disclosure provides humanized COL-1 monoclonal antibodies that retain CEA binding affinity, compared to a parent antibody. Also disclosed herein are humanized COL-1 monoclonal antibodies that have reduced immunogenicity, compared to a parent antibody. The disclosed humanized COL-1 antibodies include substitution of framework residues with residues from the corresponding positions of a homologous human sequence. In several embodiments, methods are disclosed for the use of a humanized COL-1 antibody in the detection or treatment of a CEA-expressing tumor or cell in a subject. Also disclosed is a kit including the humanized COL-1 antibodies described herein.

    摘要翻译： 本公开提供与亲本抗体相比保留CEA结合亲和力的人源化COL-1单克隆抗体。 本文还公开了与亲本抗体相比具有降低的免疫原性的人源化COL-1单克隆抗体。 公开的人源化COL-1抗体包括用来自同源人序列的相应位置的残基取代框架残基。 在几个实施方案中，公开了使用人源化COL-1抗体检测或治疗受试者中表达CEA的肿瘤或细胞的方法。 还公开了包含本文所述的人源化COL-1抗体的试剂盒。

    Framework Residue Substituted Humanized Col-1 Antibodies and Their Use
    2.
    发明申请
    Framework Residue Substituted Humanized Col-1 Antibodies and Their Use 有权
    框架残基取代人源化Col-1抗体及其用途

    公开(公告)号：US20080274055A1

    公开(公告)日：2008-11-06

    申请号：US11813092

    申请日：2005-12-30

    申请人： Syed Kashmiri ,  Rafia Mehdi Kashmiri ,  Jeffrey Schlom ,  Eduardo A. Padlan

    发明人： Syed Kashmiri ,  Rafia Mehdi Kashmiri ,  Jeffrey Schlom ,  Eduardo A. Padlan

    IPC分类号： A61K39/395 ,  C07K16/30 ,  G01N33/574 ,  A61K49/00 ,  C12N15/13 ,  C12N15/79 ,  C12N5/10 ,  A61P35/00

    CPC分类号： C07K16/3007 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/565

    摘要： The present disclosure provides humanized COL-1 monoclonal antibodies that retain CEA binding affinity, compared to a parent antibody. Also disclosed herein are humanized COL-1 monoclonal antibodies that have reduced immunogenicity, compared to a parent antibody. The disclosed humanized COL-1 antibodies include substitution of framework residues with residues from the corresponding positions of a homologous human sequence. In several embodiments, methods are disclosed for the use of a humanized COL-1 antibody in the detection or treatment of a CEA-expressing tumor or cell in a subject. Also disclosed is a kit including the humanized COL-1 antibodies described herein.

    摘要翻译： 本公开提供与亲本抗体相比保留CEA结合亲和力的人源化COL-1单克隆抗体。 本文还公开了与亲本抗体相比具有降低的免疫原性的人源化COL-1单克隆抗体。 公开的人源化COL-1抗体包括用来自同源人序列的相应位置的残基取代框架残基。 在几个实施方案中，公开了在检测或治疗受试者中表达CEA的肿瘤或细胞的情况下使用人源化COL-1抗体的方法。 还公开了包含本文所述的人源化COL-1抗体的试剂盒。

    VARIANTS OF HUMANIZED ANTI-CARCINOMA MAb CC49
    4.
    发明申请
    VARIANTS OF HUMANIZED ANTI-CARCINOMA MAb CC49 有权
    人类抗癌药物CARB CC49的变种

    公开(公告)号：US20080050810A1

    公开(公告)日：2008-02-28

    申请号：US11776437

    申请日：2007-07-11

    申请人： Syed Kashmiri ,  Eduardo Padlan ,  Jeffrey Schlom

    发明人： Syed Kashmiri ,  Eduardo Padlan ,  Jeffrey Schlom

    IPC分类号： C12N15/85 ,  C07H21/02 ,  C07H21/04 ,  C12N5/10 ,  C12N15/64

    CPC分类号： A61K49/0002 ,  A61K38/00 ,  A61K51/1045 ,  A61K2039/505 ,  C07K16/30 ,  C07K16/3046 ,  C07K16/4208 ,  C07K2317/24 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92 ,  C12N2799/026 ,  G01N33/5743

    摘要： The invention is directed towards mouse-human chimeric variants of CC49 monoclonal antibodies with minimal murine content. A first aspect of the invention provides CDR variants of humanized monoclonal antibody (HuCC49) in which less than all six (three heavy chain and three light chain) Complementarity Determining Regions (CDRs) of CC49 are present. A second aspect of the invention provides SDR variants of humanized monoclonal antibody (HuCC49) in which only Specificity Determining Regions (SDRs) of at least one CDR from CC49 are present. The invention is also directed towards biotechnological methods of making the variants and therapeutic methods of using the variants.

    摘要翻译： 本发明针对具有最小鼠含量的CC49单克隆抗体的小鼠 - 人嵌合变体。 本发明的第一方面提供了存在CC49的全部六（三个重链和三个轻链）互补决定区（CDR）的人源化单克隆抗体（HuCC49）的CDR变体。 本发明的第二方面提供了仅存在来自CC49的至少一个CDR的特异性确定区（SDR）的人源化单克隆抗体（HuCC49）的SDR变体。 本发明还涉及制备使用变体的变体和治疗方法的生物技术方法。